Limited-Stage Small Cell Lung Cancer: Is Prophylactic Cranial Irradiation Necessary?

Area of Science:

• Oncology
• Radiotherapy
• Neurology

Background:

• Prophylactic cranial irradiation (PCI) is used for limited-stage small cell lung cancer (LS-SCLC) to prevent brain metastases.
• PCI is associated with neurotoxicity, and modern imaging may improve early detection of metastases, potentially reducing PCI's utility.
• Previous studies have not consistently utilized pretreatment magnetic resonance imaging (MRI).

Purpose of the Study:

• To evaluate the association between PCI and patient outcomes in LS-SCLC using modern imaging techniques.
• To determine if PCI improves survival and reduces brain metastasis incidence in LS-SCLC patients with contemporary imaging standards.

Main Methods:

• Retrospective analysis of LS-SCLC patients treated between 2007 and 2018 with no intracranial disease at initial staging.
• Kaplan-Meier estimates for overall survival (OS) and progression-free survival (PFS) were calculated.
• Cumulative incidence of brain metastases was estimated using competing risks methodology; Cox proportional hazards models were used for multivariate analysis.

Main Results:

• PCI was associated with improved PFS (26.3 vs. 12.3 months, P=.02) and a reduced cumulative incidence of brain metastases at 2 years (10% with PCI vs. 29% without).
• In patients with negative post-treatment MRI, the 1-year incidence of brain metastases was similar (8% vs. 11%).
• PCI and treatment response were independent predictors of PFS; patients with a complete response did not benefit from PCI, unlike those with partial response or stable disease.

Conclusions:

• PCI demonstrates improved PFS and reduced early brain metastases in LS-SCLC patients.
• Patients achieving a complete response to initial therapy do not appear to benefit from PCI.
• PCI may be avoidable for specific LS-SCLC patient subsets in the era of advanced imaging.